Novo Nordisk’s cannabinoid CB1 receptor blocker has run into another problem. | Novo Nordisk’s cannabinoid CB1 receptor blocker has run into another problem. Months after sharing obesity data that ...
Ozempic's expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...
Regulators have approved the drug as a treatment for weight loss, Type 2 diabetes and lowering the risk of heart attacks and ...
has now also been approved by the US Food and Drug Administration to reduce certain risks associated with chronic kidney ...
The Food and Drug Administration has approved Ozempic ® (semaglutide) to reduce the risk of sustained estimated glomerular ...
Approval was based on results from the Phase IIIb FLOW trial, which demonstrated a 24% relative risk reduction in kidney ...
Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk won FDA approval for Ozempic in chronic kidney disease ...
When Novo Nordisk unveiled kidney outcomes data for its star GLP-1 medicine Ozempic last May, the company’s executive medical ...
Semaglutide is now approved for reducing the risk for worsening kidney disease and cardiovascular death in adults with ...
Novo Nordisk ended the phase three trial in October, a year earlier than expected, in response to positive results. At the time, the Danish company's announcement caused shares of kidney dialysis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback